Medicines A–Z
S
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 |
Sacituzumab govitecan | ||
 |
Sacubitril/Valsartan (Entresto®) | RICaD. Transfer to primary care at three months following initiation by Heart Failure specialist supported by a RICaD. |
|
|
Salbutamol | ||
 |
Salbutamol inhaler | ||
|
Salbutamol injection | ||
|
Salbutamol nebulised | ||
|
Salbutamol oral | ||
|
Salicylic acid 10% w/w in emulsifying ointment | Unlicensed special |
|
|
Salicylic acid 16.7% with lactic acid 16.7% paint (Salactol®) | ||
|
Salicylic acid 2% in white soft paraffin (100g) |
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
